Benefits and obstacles to cell therapy in neonates: The INCuBAToR (Innovative Neonatal Cellular Therapy for Bronchopulmonary Dysplasia: Accelerating Translation of Research)
Open Access
- 1 July 2021
- journal article
- review article
- Published by Oxford University Press (OUP) in Stem Cells Translational Medicine
- Vol. 10 (7), 968-975
- https://doi.org/10.1002/sctm.20-0508
Abstract
Cell-based therapies hold promise to substantially curb complications from extreme preterm birth, the main cause of death in children below the age of 5 years. Exciting preclinical studies in experimental neonatal lung injury have provided the impetus for the initiation of early phase clinical trials in extreme preterm infants at risk of developing bronchopulmonary dysplasia. Clinical translation of promising therapies, however, is slow and often fails. In the adult population, results of clinical trials so far have not matched the enticing preclinical data. The neonatal field has experienced many hard-earned lessons with the implementation of oxygen therapy or postnatal steroids. Here we briefly summarize the preclinical data that have permitted the initiation of early phase clinical trials of cell-based therapies in extreme preterm infants and describe the INCuBAToR concept (Innovative Neonatal Cellular Therapy for Bronchopulmonary Dysplasia: Accelerating Translation of Research), an evidence-based approach to mitigate the risk of translating advanced therapies into this vulnerable patient population. The INCuBAToR addresses several of the shortcomings at the preclinical and the clinical stage that usually contribute to the failure of clinical translation through (a) systematic reviews of preclinical and clinical studies, (b) integrated knowledge transfer through engaging important stakeholders early on, (c) early economic evaluation to determine if a novel therapy is viable, and (d) retrospective and prospective studies to define and test ideal eligibility criteria to optimize clinical trial design. The INCuBAToR concept can be applied to any novel therapy in order to enhance the likelihood of success of clinical translation in a timely, transparent, rigorous, and evidence-based fashion.Keywords
Funding Information
- Ontario Institute for Regenerative Medicine
- Canadian Institutes of Health Research
This publication has 63 references indexed in Scilit:
- Whole Animal Experiments Should Be More Like Human Randomized Controlled TrialsPLoS Biology, 2013
- Safety of Cell Therapy with Mesenchymal Stromal Cells (SafeCell): A Systematic Review and Meta-Analysis of Clinical TrialsPLOS ONE, 2012
- Learning curves, taking instructions, and patient safety: using a theoretical domains framework in an interview study to investigate prescribing errors among trainee doctorsImplementation Science, 2012
- A step-by-step guide to systematically identify all relevant animal studiesLaboratory Animals, 2012
- Bone Marrow Stromal Cells Attenuate Lung Injury in a Murine Model of Neonatal Chronic Lung DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2009
- Airway Delivery of Mesenchymal Stem Cells Prevents Arrested Alveolar Growth in Neonatal Lung Injury in RatsAmerican Journal of Respiratory and Critical Care Medicine, 2009
- Importance of behaviour in interventionsBMJ, 2008
- Chronic Lung Disease after Premature BirthThe New England Journal of Medicine, 2007
- Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statementCytotherapy, 2006
- Partial Liquid Ventilation with Perflubron in Premature Infants with Severe Respiratory Distress SyndromeThe New England Journal of Medicine, 1996